OpenMedicare
Start Here
Explore
Fraud
Investigations
Data
Tools
About

Footer

OpenMedicare

Independent Medicare data journalism

Sister Sites

  • OpenMedicaid
  • OpenFeds
  • OpenSpending

Explore

  • Providers
  • Procedures
  • States
  • Specialties
  • Search

Fraud Analysis

  • Still Out There (AI)
  • Fraud Overview
  • Fraud Watchlist
  • Deep Dive Profiles
  • Impossible Numbers
  • Report Fraud

Investigations

  • The Algorithm Knows
  • How We Built the Model
  • Internal Medicine Crisis
  • Florida & California Fraud
  • Million Dollar Flagged
  • All Investigations

Tools

  • Provider Lookup
  • Compare
  • Cost Calculator
  • Your Medicare Dollar
  • Downloads

About

  • About OpenMedicare
  • Methodology
  • Glossary
  • Data Sources
  • API Docs
  • Updates
Data Sources: Centers for Medicare & Medicaid Services (CMS), Medicare Provider Utilization and Payment Data
Disclaimer: This site is an independent journalism project. Data analysis and editorial content are not affiliated with or endorsed by CMS or any government agency. All spending figures are based on publicly available Medicare payment records.
Sister Sites: OpenMedicaid ยท OpenFeds ยท OpenSpending

ยฉ 2026 OpenMedicare. Independent data journalism. Built by TheDataProject.ai

Methodologyโ€ขDownload Data
  1. Home
  2. Providers
  3. Luke Dreisbach
๐ŸŽ—๏ธ
MDIndividual

Luke Dreisbach, M.D.

NPI: 1831109792
Rancho Mirage, CA
10 years of data
Hematology-Oncology
$77.2M
Total Payments
537
Beneficiaries
5.7M
Services
2.58x
Markup Ratio

Peer Comparison

99th
percentile in specialty
This provider$77.2M
Specialty median$339.6K
Rank #1 of 60 in specialty

๐Ÿ“‹ Key Findings

1Billed $77.2M over 10 years
22.58x markup ratio (above median)
399th percentile in Hematology-Oncology by payments
42.3K services/day โ€” physically implausible
53 procedures with >3x markup

โš ๏ธ This provider averages 2.3K services per working day โ€” physically unusual for an individual practitioner

Based on 5.7M total services over 10 years (250 working days/year). Learn about impossible service volumes โ†’

๐Ÿ”Ž Data Analysis

This provider's $77.2M in total Medicare payments ranks in the 99th percentile of Hematology-Oncology providers nationally.

Averaging 2.3K services per working day raises questions about billing patterns.

Medicare payments to this provider grew 129% from 2014 to 2023.

AI-generated analysis based on Medicare payment data.

Annual Medicare Payments

Annual Services Provided

Avg Payment per Service

Markup Ratio Over Time

Submitted Charges vs. Medicare Payments

Average per-service amounts submitted by the provider compared to what Medicare actually paid โ€” the gap represents the markup.

YearAvg SubmittedAvg PaidMarkup RatioGap per ServiceTotal PaymentsServicesBeneficiaries
2014$28.03$13.322.10x$14.71$4.3M322.9K52
2015$21.61$12.021.80x$9.59$4.8M397.2K52
2016$21.57$11.101.94x$10.47$6.0M543.9K52
2017$27.24$13.232.06x$14.01$7.1M534.2K50
2018$35.15$15.962.20x$19.19$8.3M519.2K49
2019$38.87$16.722.32x$22.15$9.4M560.2K51
2020$36.99$15.422.40x$21.57$10.8M697.7K55
2021$42.71$13.483.17x$29.23$7.6M566.0K58
2022$43.46$13.203.29x$30.26$9.1M691.9K57
2023$42.89$11.943.59x$30.95$9.8M824.6K61

Top Procedures (20)

J9271Injection, pembrolizumab, 1 mg
$17.9M
450.2K services$39.84/svc2.99x markup
J9299Injection, nivolumab, 1 mg
$7.4M
336.7K services$21.93/svc2.68x markup
J0897Injection, denosumab, 1 mg
$5.8M
394.1K services$14.63/svc2.23x markup
J0885Injection, epoetin alfa, (for non-esrd use), 1000 units
$3.6M
420.8K services$8.61/svc2.42x markup
J2505Injection, pegfilgrastim, 6 mg
$3.6M
1.2K services$3.0K/svc1.62x markup
J9310Injection, rituximab, 100 mg
$3.4M
5.6K services$609.40/svc1.34x markup
J9041Injection, bortezomib (velcade), 0.1 mg
$2.6M
71.0K services$36.07/svc1.67x markup
J9312Injection, rituximab, 10 mg
$2.5M
34.4K services$72.49/svc2.11x markup
J9022Injection, atezolizumab, 10 mg
$2.2M
35.2K services$63.46/svc2.85x markup
99214Established patient office or other outpatient visit, 30-39 minutes
$1.9M
21.5K services$89.80/svc2.22x markup
J9305Injection, pemetrexed, not otherwise specified, 10 mg
$1.8M
36.1K services$50.42/svc1.48x markup
J9144Injection, daratumumab, 10 mg and hyaluronidase-fihjโš  3.1x markup
$1.7M
46.4K services$37.05/svc3.10x markup
Q5111Injection, pegfilgrastim-cbqv, biosimilar, (udenyca), 0.5 mg
$1.7M
6.6K services$256.91/svc2.90x markup
96413Administration of chemotherapy into vein, 1 hour or less
$1.5M
12.9K services$116.41/svc2.35x markup
J9035Injection, bevacizumab, 10 mg
$1.4M
26.6K services$54.09/svc1.44x markup
J1569Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg
$1.3M
40.6K services$32.54/svc2.31x markup
Q5122Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mgโš  5.4x markup
$1.3M
8.3K services$156.12/svc5.39x markup
J1439Injection, ferric carboxymaltose, 1 mg
$1.1M
1.3M services$0.85/svc2.24x markup
J9395Injection, fulvestrant, 25 mg
$1.1M
20.8K services$50.49/svc2.50x markup
J9999Not otherwise classified, antineoplastic drugsโš  3.1x markup
$993.9K
107.7K services$9.23/svc3.08x markup
Show detailed table โ–พ
CodeDescriptionServicesPaymentsAvg/ServiceMarkup
J9271Injection, pembrolizumab, 1 mg450.2K$17.9M$39.842.99x
J9299Injection, nivolumab, 1 mg336.7K$7.4M$21.932.68x
J0897Injection, denosumab, 1 mg394.1K$5.8M$14.632.23x
J0885Injection, epoetin alfa, (for non-esrd use), 1000 units420.8K$3.6M$8.612.42x
J2505Injection, pegfilgrastim, 6 mg1.2K$3.6M$3.0K1.62x
J9310Injection, rituximab, 100 mg5.6K$3.4M$609.401.34x
J9041Injection, bortezomib (velcade), 0.1 mg71.0K$2.6M$36.071.67x
J9312Injection, rituximab, 10 mg34.4K$2.5M$72.492.11x
J9022Injection, atezolizumab, 10 mg35.2K$2.2M$63.462.85x
99214Established patient office or other outpatient visit, 30-39 minutes21.5K$1.9M$89.802.22x
J9305Injection, pemetrexed, not otherwise specified, 10 mg36.1K$1.8M$50.421.48x
J9144Injection, daratumumab, 10 mg and hyaluronidase-fihj46.4K$1.7M$37.053.10x
Q5111Injection, pegfilgrastim-cbqv, biosimilar, (udenyca), 0.5 mg6.6K$1.7M$256.912.90x
96413Administration of chemotherapy into vein, 1 hour or less12.9K$1.5M$116.412.35x
J9035Injection, bevacizumab, 10 mg26.6K$1.4M$54.091.44x
J1569Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg40.6K$1.3M$32.542.31x
Q5122Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg8.3K$1.3M$156.125.39x
J1439Injection, ferric carboxymaltose, 1 mg1.3M$1.1M$0.852.24x
J9395Injection, fulvestrant, 25 mg20.8K$1.1M$50.492.50x
J9999Not otherwise classified, antineoplastic drugs107.7K$993.9K$9.233.08x

Markup Analysis

Charge-to-Payment Ratio

2.58x

This provider submits charges 2.58 times higher than what Medicare actually pays.

What This Means

A markup ratio of 2.58x means for every $100 Medicare pays, this provider initially charges $258. This is higher than the national average.

Location

Rancho Mirage, CA

Provider Verification

Always verify provider credentials and location before scheduling appointments. This data reflects Medicare payments and may not include all practice locations.

Similar Providers

Other Hematology-Oncology providers in CA for peer comparison.

Luke Dreisbach (you)
$77.2M
Sachin Gupta, M.D.
$55.1M
Ravi Rao, MDโš ๏ธ
$49.1M
Michael Sherman, M.D., PHD
$38.9M
Nerses Tchekmedyian, M.D.
$38.0M
Kishore Sehgal, M.D.
$36.2M
Show detailed table โ–พ
ProviderLocationTotal PaymentsStatus
Sachin Gupta, M.D.Fresno, CA$55.1Mโœ“ Clear
Ravi Rao, MDFresno, CA$49.1Mโš ๏ธ Flagged
Michael Sherman, M.D., PHDWalnut Creek, CA$38.9Mโœ“ Clear
Nerses Tchekmedyian, M.D.Irvine, CA$38.0Mโœ“ Clear
Kishore Sehgal, M.D.Hemet, CA$36.2Mโœ“ Clear

Related

Browse
โ† Back to Provider Directory
State
All providers in CA โ†’
Specialty
All Hematology-Oncology providers โ†’
Tool
Compare this provider โ†’
Analysis
Fraud Watchlist โ†’
Search
Search all providers โ†’

Share This Provider

Share this provider's Medicare payment information

Share:

Data Sources

  • โ€ข Centers for Medicare & Medicaid Services (CMS)
  • โ€ข Medicare Provider Utilization and Payment Data (2014-2023)
  • โ€ข National Plan and Provider Enumeration System (NPPES)

Last Updated: February 2026 (data through 2023, the latest CMS release)

Note: All data is from publicly available Medicare records. OpenMedicare is an independent journalism project not affiliated with CMS.

Believe this data is inaccurate? Dispute this data